---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-134238"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:53:30.513263+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cytek Q1 revenue $44.9M (+21% YoY); organic revenue up 11%; reaffirms 2024 guidance

## Summary
- Total revenue $44.9M, +21% YoY; organic revenue (ex-Luminex) $37.3M, +11%.
- Gross profit margin 51% (down from 57%); adjusted gross margin 55% (down from 59%).
- Net loss $6.2M vs $6.8M loss; Adjusted EBITDA loss $0.7M vs $2.5M loss.
- Reaffirms 2024 revenue guidance $203M-$213M (5-10% growth); expects positive net income for FY2024.
- Appointed William McCombe as CFO; opened new facility in Wuxi, China; received NMPA approvals.

## SEC filing metadata
- accession: 0001193125-24-134238
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312524134238/0001193125-24-134238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312524134238/d814789d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-134238
- JSON: https://secwatch.observer/filing/0001193125-24-134238.json
- Plain text: https://secwatch.observer/filing/0001193125-24-134238.txt

## Key facts
- Earnings Releases
  Cytek Biosciences, Inc. reported the quarter ended March 31, 2024 results: revenue $44.9 million, net income $6.2 million. Guidance reaffirmed.
  - Period: the quarter ended March 31, 2024
  - Revenue: $44.9 million
  - Net income: $6.2 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Total revenue was $44.9 million, representing a 21% increase over the corresponding period of 2023 • Organic revenue was $37.3 million, representing an increase of 11% compared to the first quarter of 2023 •
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312524134238/0001193125-24-134238-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.